Literature DB >> 7759075

Age at diagnosis as an indicator of eligibility for BRCA1 DNA testing in familial breast cancer.

R S Cornelis1, H F Vasen, H Meijers-Heijboer, D Ford, M van Vliet, A A van Tilborg, F J Cleton, J G Klijn, F H Menko, P Meera Khan.   

Abstract

We searched for criteria that could indicate breast cancer families with a high prior probability of being caused by the breast/ovarian cancer susceptibility locus BRCA1 on chromosome 17. To this end, we performed a linkage study with 59 consecutively collected Dutch breast cancer families, including 16 with at least one case of ovarian cancer. We used an intake cut-off of at least three first-degree relatives with breast and/or ovarian cancer at any age. Significant evidence for linkage was found only among the 13 breast cancer families with a mean age at diagnosis of less than 45 years. An unexpectedly low proportion of the breast-ovarian cancer families were estimated to be linked to BRCA1, which could be due to a founder effect in the Dutch population. Given the expected logistical problems in clinical management now that BRCA1 has been identified, we propose an interim period in which only families with a strong positive family history for early onset breast and/or ovarian cancer will be offered BRCA1 mutation testing.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7759075     DOI: 10.1007/BF00223866

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  15 in total

1.  A second-generation linkage map of the human genome.

Authors:  J Weissenbach; G Gyapay; C Dib; A Vignal; J Morissette; P Millasseau; G Vaysseix; M Lathrop
Journal:  Nature       Date:  1992-10-29       Impact factor: 49.962

2.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

3.  Abundant class of human DNA polymorphisms which can be typed using the polymerase chain reaction.

Authors:  J L Weber; P E May
Journal:  Am J Hum Genet       Date:  1989-03       Impact factor: 11.025

4.  Effect on a Dutch family of predictive DNA-testing for hereditary breast and ovarian cancer.

Authors:  A C de Wit; E J Meijers-Heijboer; A Tibben; P G Frets; J G Klijn; P Devilee; M F Niermeijer
Journal:  Lancet       Date:  1994-07-16       Impact factor: 79.321

5.  Genetic linkage analysis in familial breast and ovarian cancer: results from 214 families. The Breast Cancer Linkage Consortium.

Authors:  D F Easton; D T Bishop; D Ford; G P Crockford
Journal:  Am J Hum Genet       Date:  1993-04       Impact factor: 11.025

6.  Computer-simulation methods in human linkage analysis.

Authors:  J Ott
Journal:  Proc Natl Acad Sci U S A       Date:  1989-06       Impact factor: 11.205

7.  Strategies for multilocus linkage analysis in humans.

Authors:  G M Lathrop; J M Lalouel; C Julier; J Ott
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

8.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.

Authors:  D F Easton; D Ford; D T Bishop
Journal:  Am J Hum Genet       Date:  1995-01       Impact factor: 11.025

9.  Familial male breast cancer is not linked to the BRCA1 locus on chromosome 17q.

Authors:  M R Stratton; D Ford; S Neuhasen; S Seal; R Wooster; L S Friedman; M C King; V Egilsson; P Devilee; R McManus
Journal:  Nat Genet       Date:  1994-05       Impact factor: 38.330

10.  Genetic analysis of breast cancer in the cancer and steroid hormone study.

Authors:  E B Claus; N Risch; W D Thompson
Journal:  Am J Hum Genet       Date:  1991-02       Impact factor: 11.025

View more
  6 in total

Review 1.  Triple-negative breast cancer: present challenges and new perspectives.

Authors:  Franca Podo; Lutgarde M C Buydens; Hadassa Degani; Riet Hilhorst; Edda Klipp; Ingrid S Gribbestad; Sabine Van Huffel; Hanneke W M van Laarhoven; Jan Luts; Daniel Monleon; Geert J Postma; Nicole Schneiderhan-Marra; Filippo Santoro; Hans Wouters; Hege G Russnes; Therese Sørlie; Elda Tagliabue; Anne-Lise Børresen-Dale
Journal:  Mol Oncol       Date:  2010-04-24       Impact factor: 6.603

2.  Predicting adaptation to presymptomatic DNA testing for late onset disorders: who will experience distress? Rotterdam Leiden Genetics Workgroup.

Authors:  A C DudokdeWit; A Tibben; H J Duivenvoorden; M F Niermeijer; J Passchier
Journal:  J Med Genet       Date:  1998-09       Impact factor: 6.318

3.  A high proportion of novel mutations in BRCA1 with strong founder effects among Dutch and Belgian hereditary breast and ovarian cancer families.

Authors:  T Peelen; M van Vliet; A Petrij-Bosch; R Mieremet; C Szabo; A M van den Ouweland; F Hogervorst; R Brohet; M J Ligtenberg; E Teugels; R van der Luijt; A H van der Hout; J J Gille; G Pals; I Jedema; R Olmer; I van Leeuwen; B Newman; M Plandsoen; M van der Est; G Brink; S Hageman; P J Arts; M M Bakker; P Devilee
Journal:  Am J Hum Genet       Date:  1997-05       Impact factor: 11.025

4.  Psychological distress in applicants for predictive DNA testing for autosomal dominant, heritable, late onset disorders. The Rotterdam/Leiden Genetics Workgroup.

Authors:  A C DudokdeWit; A Tibben; H J Duivenvoorden; P G Frets; M W Zoeteweij; M Losekoot; A van Haeringen; M F Niermeijer; J Passchier
Journal:  J Med Genet       Date:  1997-05       Impact factor: 6.318

5.  Screening for BRCA2 mutations in 81 Dutch breast-ovarian cancer families.

Authors:  T Peelen; M van Vliet; A Bosch; G Bignell; H F Vasen; J G Klijn; H Meijers-Heijboer; M Stratton; G J van Ommen; C J Cornelisse; P Devilee
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

6.  An open-label, pilot study of veliparib and lapatinib in patients with metastatic, triple-negative breast cancer.

Authors:  Erica M Stringer-Reasor; Jori E May; Eva Olariu; Valerie Caterinicchia; Yufeng Li; Dongquan Chen; Deborah L Della Manna; Gabrielle B Rocque; Christos Vaklavas; Carla I Falkson; Lisle M Nabell; Edward P Acosta; Andres Forero-Torres; Eddy S Yang
Journal:  Breast Cancer Res       Date:  2021-03-04       Impact factor: 6.466

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.